Category Archives: Deals

Merck and Novartis Down in Q3 Financial Reports

By Jennifer Markarian Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
Also posted in Global, Guest Blog, leadership | Tagged , , , , | Leave a comment

New Non-Profit Alliance of Big Pharma Firms

By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Also posted in Biotech, Guest Blog | Tagged , , , , , , , , , , | Leave a comment

Bristol-Myers Squibb's Summertime Blues

The sun was shining, savory scents were floating out from the grill, the lemonade was mixed and the table was set. But then dark clouds blew in and settled overhead. Bristol-Myers Squibb’s (BMS) picnic got rained out this summer. One element of the rain out was forecasted long ago; Plavix, the multibillion dollar blood-thinner, second […]
Also posted in Advertising, Biotech, compliance, FDA, Legal, Marketing, pricing, R&D, Regulatory, Safety, Sales, Strategy | Tagged , , , , , | Leave a comment

The Cost of Pharma Divorce

Final: THE COST OF PHARMA DIVORCE Corporate spin-offs are on the rise across the pharmaceutical sector, but at what cost to shareholders? Brian McGilligan, AVP, Life Sciences Program Management Consulting Lead at Cognizant argues that in haste to obtain decree absolute, demerging businesses could be threatening their long term viability. Demergers are in fashion again. […]
Also posted in Global, Guest Blog | Tagged , , | 1 Comment

GSK: A Rebuffed Suitor for the Moment

By Patricia Van Arnum. Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share.  Although rejecting GSK’s initial bid, HGS kept the door open for other suitors, including again GSK. HGS has authorized its board of directors to explore strategic alternatives for the company, including a […]
Also posted in Guest Blog | Tagged , , , , | 1 Comment
  • Categories

  • Meta